

Anti-CTLA-4 [9D9] Standard Size, 50 µg, Ab01018-1.169 View online

## Anti-CTLA-4 [9D9] Standard Size Ab01018-1.169

This is bispecific mouse IgG1-D265A featuring a C-terminal anti-mOX40 scFv (based on the clone OX86) fusion.

This is a bispecific anti-mouse antibody created by fusing anti-mOX40 scFv domains to the C-terminus of the heavy chains of the anti-mouse CTLA-4 antibody clone 9D9 in a mouse IgG1 D265A format. The mouse IgG1 D265A format is an Fc-silenced format, preventing ADCC and CDC.

**Isotype and Format:** Mouse Bispecific, anti-mOX40, Bispecific antibody, Kappa **Clone Number:** 9D9

**Alternative Name(s) of Target:** CD152; CTLA4; Cytotoxic T-Lymphocyte Associated Protein 4; Insulin-Dependent Diabetes Mellitus 12; Celiac Disease 3; Ligand And Transmembrane Spliced Cytotoxic T Lymphocyte Associated Antigen 4; Cytotoxic T Lymphocyte Associated Antigen 4 Short Spliced Fo

UniProt Accession Number of Target Protein: P09793

Published Application(s): Block, IF

Published Species Reactivity: Mouse

Immunogen: The antibody was raised against CTLA-4.

**Specificity:** The antibody is specific for CTLA-4.

**Application Notes:** The antibody has been used to block CTLA-4 and has been shown to enhance T-cell immunity against tumours (Quezada et al, 2006). 9D9 also has an anti-B16/BL6 melanoma effect in non-irradiated tumour-bearing recipients when given as combinatorial therapy with Gvax (Peggs et al, 2009). Selby et al. (PMID: 24777248) show how conversion of the original mouse IgG2b to a mouse IgG2a greatly increases anti-tumor activity of the 9D9 antibody in both MC38 (C57BL/6 mice) and CT26 (BALB/c mice) models. This mechanism both involves blockade of CTLA4 as well as depletion of tumor-infiltrating regulatory T-cells. Fc Silent antibodies were shown to have reduced anti-tumor activity as they did not deplete tumor infiltrating regulatory T-cells, however they lead to expansion of peripheral Tregs.

**Antibody First Published in:** Simpson T et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma J Exp Med. 2013 Aug 26; 210(9): 1695–1710. PMID:23897981

**Note on publication:** Describes the characterisation of the Fcγ receptor-dependent activity of 9D9 on the T reg cell compartment.

## **Product Form**

Size: 50 μg Purified antibody.
Purification: Protein A affinity purified
Supplied In: PBS with 0.02% Proclin 300.
Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at - 20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.